EGFR and non-small cell lung carcinoma: As a proof of principle, a pilot study conducted in 17 patients with non-small cell lung cancer showed that saliva assays conducted using EFIRM perform accurately, non-invasively, and rapidly compared with biopsy tissue-based testing for EGFR mutation status and can be used in continuous monitoring during treatment (84).